{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:56:42Z","timestamp":1793325402340,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["23PRE1014444"],"award-info":[{"award-number":["23PRE1014444"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19CDA34590001"],"award-info":[{"award-number":["19CDA34590001"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["916172"],"award-info":[{"award-number":["916172"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R41NS130812-01"],"award-info":[{"award-number":["1R41NS130812-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM008076"],"award-info":[{"award-number":["T32GM008076"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jconrel.2024.07.070","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T15:25:12Z","timestamp":1724685912000},"page":"425-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Nanocarriers' repartitioning of drugs between blood subcompartments as a mechanism of improving pharmacokinetics, safety, and efficacy"],"prefix":"10.1016","volume":"374","author":[{"given":"Michael H.","family":"Zaleski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Omo-Lamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam S.","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob W.","family":"Myerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Glassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahily","family":"Reyes-Esteves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manthan N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina D.","family":"Peshkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Axelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir R.","family":"Muzykantov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar A.","family":"Marcos-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.07.070_bb0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11883-016-0586-1","article-title":"Sphingosine-1-phosphate signaling in endothelial disorders","volume":"18","author":"Sanchez","year":"2016","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0010","doi-asserted-by":"crossref","first-page":"18315","DOI":"10.1073\/pnas.1416166111","article-title":"Impact of an immune modulator fingolimod on acute ischemic stroke","volume":"111","author":"Fu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCRESAHA.120.316711","article-title":"Endothelial S1P1 signaling counteracts infarct expansion in ischemic stroke","volume":"128","author":"Nitzsche","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0020","doi-asserted-by":"crossref","first-page":"17962","DOI":"10.1039\/c3cp53148a","article-title":"Study of aqueous phase aggregation of FTY720 (fingolimod hydrochloride) and its effect on DMPC liposomes using fluorescent molecular probes","volume":"15","author":"Swain","year":"2013","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0025","article-title":"Clinical pharmacology and biopharmaceutics review(s)","volume":"22-527","author":"Center for Drug Evaluation and Research","year":"2010","journal-title":"Fingolimod. Appl."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0035","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1007\/s12274-018-2152-3","article-title":"Strategies to improve micelle stability for drug delivery","volume":"11","author":"Lu","year":"2018","journal-title":"Nano Res."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0040","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/la203974f","article-title":"pH-sensitive surfactants from lysine: assessment of their cytotoxicity and environmental behavior","volume":"28","author":"Colomer","year":"2012","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejpb.2016.09.015","article-title":"Correlation among chemical structure, surface properties and cytotoxicity of N-acyl alanine and serine surfactants","volume":"109","author":"Perinelli","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/01.STR.0000196957.55928.ab","article-title":"Time is brain--quantified","volume":"37","author":"Saver","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/11596550-000000000-00000","article-title":"Clinical pharmacokinetics of fingolimod","volume":"51","author":"David","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0060","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s11033-020-05361-2","article-title":"Biological barriers, and the influence of protein binding on the passage of drugs across them","volume":"47","author":"Wanat","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/17425241003610633","article-title":"Drug delivery by red blood cells: vascular carriers designed by mother nature","volume":"7","author":"Muzykantov","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0070","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1124\/dmd.105.009001","article-title":"Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(\u22124-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses","volume":"34","author":"Meno-Tetang","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.molstruc.2013.09.053","article-title":"Clinical relevance of drug binding to plasma proteins","volume":"1077","author":"Ascenzi","year":"2014","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0085","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1177\/1352458513493035","article-title":"Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient","volume":"19","author":"Lysandropoulos","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0090","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P4.2-038","article-title":"Autoimmune hemolytic Anemia after treatment with Fingolimod: a case report (P4.2-038)","volume":"92","author":"Husain","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2019-ABN-2.156","article-title":"176 Fingolimod associated immune haemolytic anaemia","volume":"90","author":"AlMasri","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome(\u00ae)): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/17425247.2015.961418","article-title":"Endothelial nanomedicine for the treatment of pulmonary disease","volume":"12","author":"Brenner","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0115","doi-asserted-by":"crossref","first-page":"11147","DOI":"10.1021\/acs.chemrev.5b00116","article-title":"Clinical translation of nanomedicine","volume":"115","author":"Min","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0120","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/jps.21916","article-title":"Significance of protein binding in pharmacokinetics and pharmacodynamics","volume":"99","author":"Schmidt","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0125","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/jps.23614","article-title":"Plasma protein binding: from discovery to development","volume":"102","author":"Bohnert","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6997(24)01329-2","article-title":"Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics","volume":"49","author":"Hinderling","year":"1997","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1749-6632.1971.tb46890.x","article-title":"Factors affecting drug metabolism","volume":"179","author":"Gillette","year":"1971","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0140","series-title":"Fundamentals of Matrix Algebra","author":"Hartman","year":"2011"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0145","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3109\/00365510903266069","article-title":"Parameterization of red blood cell elongation index--shear stress curves obtained by ektacytometry","volume":"69","author":"Baskurt","year":"2009","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0150","first-page":"71","article-title":"Peripheral blood film - a review","volume":"12","author":"Adewoyin","year":"2014","journal-title":"Ann. Ib. Postgrad. Med."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0155","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1073\/pnas.1912012117","article-title":"Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier","volume":"117","author":"Marcos-Contreras","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0160","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.neuroimage.2012.07.018","article-title":"Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders","volume":"63","author":"Montagne","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10246","article-title":"Nanoparticles in the clinic: an update post COVID-19 vaccines","volume":"6","author":"Anselmo","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0170","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of particle size and polydispersity index on the clinical applications of Lipidic Nanocarrier systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0185","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jconrel.2011.09.098","article-title":"The journey of a drug-carrier in the body: an anatomo-physiological perspective","volume":"161","author":"Bertrand","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0190","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.actbio.2021.06.008","article-title":"Isolation methods commonly used to study the liposomal protein corona suffer from contamination issues","volume":"130","author":"Kristensen","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0195","author":"Center for Drug Evaluation and Research (CDER)"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0200","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.addr.2016.02.007","article-title":"Red blood cells: supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems","volume":"106","author":"Villa","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0205","first-page":"680","article-title":"Effects of weekly blood collection in C57BL\/6 mice","volume":"50","author":"Raabe","year":"2011","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0210","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Immordino","year":"2006","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0215","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1208\/s12248-012-9330-0","article-title":"Challenges in development of targeted liposomal therapeutics","volume":"14","author":"Sawant","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0220","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood.V76.10.2125.2125","article-title":"Effect of hemoglobin oxidation products on the stability of red cell membrane skeletons and the associations of skeletal proteins: correlation with a release of hemin","volume":"76","author":"Jarolim","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0225","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/voxs.12331","article-title":"Role of red blood cells in haemostasis and thrombosis","volume":"12","author":"Litvinov","year":"2017","journal-title":"ISBT Sci. Ser."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0230","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/STROKEAHA.115.011238","article-title":"Thromboinflammation in stroke brain damage","volume":"47","author":"De Meyer","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0235","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jconrel.2019.03.008","article-title":"Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain","volume":"301","author":"Marcos-Contreras","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0240","first-page":"341","article-title":"Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha","volume":"6","author":"Feuerstein","year":"1994","journal-title":"Cerebrovasc. Brain Metab. Rev."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0245","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0149-7634(95)00026-7","article-title":"The role of inflammation and cytokines in brain injury","volume":"20","author":"Arvin","year":"1996","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041057","article-title":"Emerging roles of vascular cell adhesion Molecule-1 (VCAM-1) in immunological disorders and Cancer","volume":"19","author":"Kong","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0255","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/s41467-018-05079-7","article-title":"Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude","volume":"9","author":"Brenner","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0260","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jconrel.2015.09.055","article-title":"Targeted endothelial nanomedicine for common acute pathological conditions","volume":"219","author":"Shuvaev","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0265","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood-2004-05-1714","article-title":"ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs","volume":"105","author":"Muro","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0270","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0275","first-page":"3445","article-title":"Animal models of ischemic stroke and their application in clinical research","volume":"9","author":"Fluri","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0280","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0285","first-page":"461","article-title":"The role of microglia and myeloid immune cells in acute cerebral ischemia","volume":"8","author":"Benakis","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0290","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.nano.2013.08.001","article-title":"A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery","volume":"10","author":"Mao","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0295","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1016\/j.biomaterials.2013.04.063","article-title":"Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells","volume":"34","author":"Yu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0300","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1515\/nanoph-2022-0496","article-title":"A pH-sensitive liposomal co-delivery of fingolimod and ammonia borane for treatment of intracerebral hemorrhage","volume":"11","author":"Gong","year":"2022","journal-title":"Nanophotonics"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0305","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1021\/acsabm.2c00349","article-title":"Modulating Fingolimod (FTY720) anti-SARS-CoV-2 activity using a PLGA-based drug delivery system","volume":"5","author":"Miranda","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0310","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2147\/IJN.S156328","article-title":"Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy","volume":"13","author":"Wu","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0315","doi-asserted-by":"crossref","first-page":"8238","DOI":"10.1021\/jm5007935","article-title":"Rational use of plasma protein and tissue binding data in drug design","volume":"57","author":"Liu","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0320","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0325","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3389\/fphar.2018.00790","article-title":"Current trends and challenges in the clinical translation of Nanoparticulate nanomedicines: pathways for translational development and commercialization","volume":"9","author":"Hua","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0330","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2018.06.023","article-title":"Unintended effects of drug carriers: big issues of small particles","volume":"130","author":"Parhiz","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0335","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.2147\/IJN.S168808","article-title":"Main trends of immune effects triggered by nanomedicines in preclinical studies","volume":"13","author":"Halamoda-Kenzaoui","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.07.070_bb0340","article-title":"Combating Complement\u2019s deleterious effects on nanomedicine by conjugating complement regulatory proteins to nanoparticles","volume":"34","author":"Wang","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.07.070_bb0345","article-title":"Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins","author":"Li","year":"2023","journal-title":"Nat. Nanotechnol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:43:15Z","timestamp":1741239795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924005285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":68,"alternative-id":["S0168365924005285"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.070","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanocarriers' repartitioning of drugs between blood subcompartments as a mechanism of improving pharmacokinetics, safety, and efficacy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}